- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01415544
Comparison of Noninvasive Blood Glucose Concentrations Relative to Finger Capillary Blood Glucose References
An Evaluation and Comparison of Noninvasive Blood Glucose Concentrations Relative to Finger Capillary Blood Glucose References
Studie Overzicht
Toestand
Gedetailleerde beschrijving
Currently, individuals with diabetes must use an invasive finger stick methodology for the determination of their blood glucose levels. Although current technology glucose meters use a smaller amount of blood than older generation meters, the pain and inconvenience associated with this invasive measurement is the number one reason cited for inadequate or infrequent blood glucose monitoring. In fact up to 67% of patients with diabetes fail to routinely monitor their blood glucose levels. A survey of 1895 patients showed that finger soreness was the most common reason given for self-reported noncompliance with testing recommendations, followed by pain, inconvenience, fear of needles, and "other" (including cost), (Diabetes Care August 2001 vol. 24 no. 8 1502-1503). The ability to make a painless blood glucose measurement using only light would address the pain and inconvenience issues associated with current technology glucose meters.
The initial application of the technology is associated with the monitoring of Gestational Diabetes. The International Association of Diabetes and Pregnancy Study Groups (IADPSG) recently released recommendations for diagnosing gestational diabetes, as well as clarifying the benefits of treatment (Diabetes Care, 2010;33:676-682). The IADPSG cited research that found significant graded relationships between increasing maternal glucose levels and the frequency of four primary and five secondary outcomes. For example, with a 1-standard deviation increase in maternal fasting, 1-hour, and 2-hour plasma glucose levels, there was a corresponding 38%, 46%, and 38% increased risk, respectively, in the primary outcome of birth weight >90th percentile, and a 5%, 18%, and 16% increased risk, respectively, of the secondary outcome of premature delivery before 37 weeks gestation (N Engl J Med 2008;358:1991-2002).
Studietype
Inschrijving (Verwacht)
Contacten en locaties
Studie Locaties
-
-
New Mexico
-
Albuquerque, New Mexico, Verenigde Staten, 87106
- Lovelace Scientific Resources
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Beschrijving
Inclusion Criteria:
- Female at least 20 years of age but not older than 50 years of age
- Female with Type I or Gestational diabetes based on ADA criteria
- Female with Type II diabetes and A1c of greater than 7.0 as measured on a Bayer A1C Now meter
- May include female healthy volunteers.
Exclusion Criteria:
- Subject requires hemo-dialysis
- Severe heart disease as evidenced by peripheral edema
- Liver disease as evidenced by jaundice
- Active alcohol or drug abuse
- Body Mass Index (BMI) > 35 kg/m2
- Hand size too large to fit in the optical measurement instrumentation
- Middle finger width of less than 5 mm
- Skin damage at optical sampling site on hand
- Currently taking prednisone or other systemic steroids
- Tattoo at the optical sampling site
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
Cohorten en interventies
Groep / Cohort |
---|
Type 2 Diabetes
Those previously diagnosed with type 2 diabetes
|
Type 1 Diabetes
Those previously diagnosed with type 1 diabetes
|
Gestational Diabetes
Those that are currently diagnosed with gestational diabetes
|
Healthy Human Volunteers
Those that have not been diagnosed with any type of diabetes
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Calibrate near-infrared spectroscopy-based glucose meter
Tijdsspanne: 1 year
|
The collection of capillary blood glucose and noninvasive data will allow the calibration of the noninvasive systems and subsequently evaluate performance via a validation study.
The paired NIR spectrum and blood reference data acquired during calibration will be processed using multivariate regression techniques to create a calibration model.
Results will be compared using a Clark error grid.
|
1 year
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Compare Noninvasive to invasive techniques
Tijdsspanne: 1 year
|
Comparison of noninvasive glucose measurement performance versus standard invasive reference.
Invasive measurements are made by obtaining capillary blood glucose measurements and then measuring blood on a Yellow Springs Instrument (YSI).
Due to the fact that instrumentation drift and subject physiological changes can adversely influence measurement performance, the study is specifically designed to examine performance over an appropriate period of time with a reasonable distribution of subject variance.
Results will be compared using a Clark error grid.
|
1 year
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Walter Forman, MD, Lovelace Scientific Resources
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Verwacht)
Studie voltooiing (Verwacht)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 10-0020
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Diabetes type 1
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.VoltooidDiabetes mellitus, type 1 | Diabetes type 1 | Diabetestype1 | Diabetes mellitus type 1 | Auto-immuun diabetes | Diabetes Mellitus, insulineafhankelijk | Jeugddiabetes | Diabetes, auto-immuunziekte | Insulineafhankelijke diabetes mellitus 1 | Diabetes Mellitus, insulineafhankelijk, 1 | Diabetes Mellitus,... en andere voorwaardenVerenigde Staten
-
Capillary Biomedical, Inc.VoltooidDiabetes mellitus, type 1 | Diabetes type 1 | Diabetes mellitus type 1 | Diabetes Mellitus, insulineafhankelijk, 1Australië
-
University of California, San FranciscoJuvenile Diabetes Research FoundationVoltooidDiabetes mellitus type 1 | Diabetes mellitus, type I | Insulineafhankelijke diabetes mellitus 1 | Diabetes Mellitus, insulineafhankelijk, 1 | IDDMVerenigde Staten, Australië
-
Poznan University of Medical SciencesOnbekendDiabetes mellitus type 1 | Remissie van diabetes type 1 | Chronische complicaties van diabetesPolen
-
Capillary Biomedical, Inc.BeëindigdDiabetes type 1 | Diabetes mellitus type 1 | Diabetes mellitus, type I | Diabetes Mellitus, insulineafhankelijk, 1 | IDDMOostenrijk
-
Eledon PharmaceuticalsIngetrokkenBroze type 1 diabetes mellitusVerenigde Staten
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)VoltooidDiabetes mellitus type 1 | T1DM | T1D | Nieuwe diabetes mellitus type 1Verenigde Staten, Australië
-
Shanghai Changzheng HospitalWervingBroze type 1 diabetes mellitusChina
-
University Hospital Inselspital, BerneVoltooidDiabetes complicaties | Diabetes mellitus type 1Zwitserland
-
Spiden AGDCB Research AGWervingDiabetes mellitus type 1 | Diabetes mellitus type 1 met hypoglykemie | Diabetes mellitus type 1 met hyperglykemieZwitserland